

## Washington State Health Care Authority **Prescription Drug Program**

P.O. Box 91132 • Seattle, Washington 98111-9232 206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • www.rx.wa.gov

October 15, 2012

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority (Medicaid/Uniform Medical Plan) and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective December 1, 2012:

Asthma Controller Drugs – Inhaled Corticosteroid reviewed 8/17/2011		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
beclomethasone dipropionate	Qvar <sup>®</sup> aerosol	Yes	Yes	Yes
budesonide	budesonide suspension	Yes	Yes	Yes
	Pulmicort® suspension 1mg/2ml	Yes	Yes	Yes
fluticasone propionate	Flovent Diskus® aerosol powder	Yes	Yes	Yes
	breath activated			
	Flovent HFA® aerosol	Yes	Yes	Yes

The effect of this recommendation is to make Pulmicort Flexhaler® non-preferred on the PDL.

Asthma Controller Drugs – Inhaled Corticosteroid Combinations		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
fluticasone propionate;	Advair Diskus® aerosol all strengths	Yes	Yes	Yes
salmeterol xinafoate	Advair HFA® aerosol	Yes	Yes	Yes

The effect of this recommendation is to make Symbicort® non-preferred on the PDL.

Asthma Controller Drugs – Leukotriene Modifier		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
montelukast sodium	montelukast sodium tablet	Yes	Yes	Yes
zafirlukast	zafirlukast tablet	Yes	Yes	Yes

The effect of this recommendation is to make Singulair non-preferred on the PDL and to make montelukast sodium and zafirlukast preferred on the PDL.

Asthma Controller Drugs – Long Acting Beta Agonists		Agency Coverage		
Ingredient Name	Label Name of Preferred Product	L&I	Medicaid	UMP
salmeterol xinafoate	Serevent Diskus® aerosol powder	Yes	Yes	Yes
	breath activated			

The effect of this recommendation is to make Foradil Aerolizer<sup>®</sup> non-preferred on the PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL at: <a href="http://www.rx.wa.gov/documents/washingtonpdl.pdf">http://www.rx.wa.gov/documents/washingtonpdl.pdf</a>

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at <a href="leta.evaskus@hca.wa.gov">leta.evaskus@hca.wa.gov</a>.

Sincerely,

Duane Thurman

Director, Prescription Drug Programs
Washington State Health Care Authority